Nintedanib can be used safely and effectively for idiopathic pulmonary fibrosis with predicted forced vital capacity ≤ 50%: A multi-center retrospective analysis.

Published on Aug 27, 2020in PLOS ONE2.74
· DOI :10.1371/JOURNAL.PONE.0236935
Satoru Senoo5
Estimated H-index: 5
(Okayama University),
Nobuaki Miyahara33
Estimated H-index: 33
(RMIT: RMIT University)
+ 17 AuthorsKatsuyuki Kiura68
Estimated H-index: 68
(Okayama University)
BACKGROUND Nintedanib is a multi-kinase inhibitor approved for idiopathic pulmonary fibrosis (IPF); however, its efficacy and safety for patients with IPF and restricted pulmonary function remain unclear. Therefore, the objective of this study was to determine the efficacy and safety of nintedanib for patients with IPF and forced vital capacity (FVC) ≤ 50%. METHODS This was a multi-center retrospective study performed by the Okayama Respiratory Disease Study Group. Patients were allocated into FVC ≤ 50% and FVC > 50% groups based on their predicted FVC. The primary endpoints were FVC changes from baseline after 6 and 12 months. RESULTS 45 patients were eligible for the study. 18 patients had FVC ≤ 50%, and 27 patients had FVC > 50%. Overall, 31 and 19 patients underwent pulmonary function tests at 6 and 12 months after initiating nintedanib, respectively. FVC changes from baseline at 6 and 12 months after initiating nintedanib were comparable between the two groups. Adverse events were seen in all patients, and the rates of patients who discontinued nintedanib were also comparable (38.9% vs. 37.0%, p = 1.000). Multiple regression analysis showed that age and forced expiratory volume in 1 second (FEV1)/FVC were negatively correlated with changes in FVC at 6 months after initiating nintedanib. CONCLUSIONS Our data suggest that nintedanib can be a useful agent for IPF patients, including those with a low FVC, and that age and FEV1/FVC are predictive markers for changes in FVC following nintedanib treatment.
📖 Papers frequently viewed together
14 Citations
5 Authors (Martin Kolb, ..., Luca Richeldi)
14 Citations
8 Authors (Martin Kolb, ..., Roland M. du Bois)
119 Citations
#1Hee-Young Yoon (UOU: University of Ulsan)H-Index: 9
#2Sojung Park (UOU: University of Ulsan)H-Index: 10
Last. Jin Woo Song (UOU: University of Ulsan)H-Index: 26
view all 4 authors...
Phase 3 trials have shown that nintedanib reduces the decline in forced vital capacity (FVC) in patients with mild-to-moderate idiopathic pulmonary fibrosis (IPF) with acceptable safety profiles; however, its effects on advanced IPF are unclear. We investigated the efficacy and safety of nintedanib in patients with advanced IPF. Prospective data were obtained from 108 IPF patients administered at least one dose of nintedanib. Of these patients, 47.2% had advanced IPF (FVC < 50% predicted, or dif...
38 CitationsSource
#1Mitsuhiro Abe (Chiba University)H-Index: 7
#2Kenji Tsushima (Chiba University)H-Index: 9
Last. Koichiro Tatsumi (Chiba University)H-Index: 55
view all 7 authors...
Introduction: The INPULSIS-ON trial demonstrated that nintedanib reduced decline in forced vital capacity (FVC) and low pulmonary function (%FVC < 50%) of patients with idiopathic pulmonary fibrosis (IPF). However, there is no sufficient evidence in real world. Objectives: Reveal the utility and adverse events of nintedanib for severe IPF patients. Methods: This was a single-center retrospective study. Patients who met the eligibility criteria of the INPULSIS trial (%FVC ≥ 50%; %DLCO [diffusing ...
12 CitationsSource
Background: This document provides clinical recommendations for the diagnosis of idiopathic pulmonary fibrosis (IPF). It represents a collaborative effort between the American Thoracic Society, Eur...
1,046 CitationsSource
#1Kevin R. Flaherty (UM: University of Michigan)H-Index: 76
#2Martin Kolb (McMaster University)H-Index: 63
Last. Luca Richeldi (UCSC: Catholic University of the Sacred Heart)H-Index: 69
view all 6 authors...
In the Phase III INPULSIS® trials, nintedanib reduced the annual rate of decline in forced vital capacity (FVC) versus placebo in patients with idiopathic pulmonary fibrosis (IPF). We conducted post hoc analyses of the distribution of changes in FVC in the INPULSIS® trials and FVC changes in the open-label extension trial INPULSIS®-ON in subgroups of patients based on whether patients had shown an improvement or no decline in FVC in INPULSIS®. Analyses were descriptive. Based on the annual rate ...
16 CitationsSource
#1Sakae Homma (Toho University)H-Index: 31
#2Masashi Bando (Jichi Medical University)H-Index: 22
Last. Kentaro Watanabe (Fukuoka University)H-Index: 24
view all 34 authors...
Abstract Idiopathic pulmonary fibrosis (IPF) is a disease of unknown etiology which accounts for a large proportion of cases of idiopathic interstitial pneumonia. It has a very poor prognosis with a 5-year survival rate of 30% or below, and so far there has been no guideline in Japan offering an established effective therapy based on evidence. In addition to the establishment of basic therapies, there is also an urgent need to establish therapies to deal with complications, as death occurs in ma...
32 CitationsSource
#1Sergio HarariH-Index: 38
#2Antonella CaminatiH-Index: 18
Last. Paola RottoliH-Index: 34
view all 23 authors...
Background: Two therapeutic options are currently available for patients with mild-to-moderate idiopathic pulmonary fibrosis (IPF): pirfenidone and nintedanib. To date, there is still insufficient data on the efficacy of these 2 agents in patients with more severe disease. Objectives: This national, multicenter, retrospective real-life study was intended to determine the impact of nintedanib on the treatment of patients with severe IPF. Methods: All patients included had severe IPF and had to ha...
27 CitationsSource
#1Wim Wuyts (Katholieke Universiteit Leuven)H-Index: 40
#2Martin Kolb (McMaster University)H-Index: 63
Last. Ganesh Raghu (UW: University of Washington)H-Index: 91
view all 6 authors...
In the Phase III INPULSIS® trials, 52 weeks’ treatment with nintedanib reduced decline in forced vital capacity (FVC) versus placebo in patients with idiopathic pulmonary fibrosis (IPF). Patients who completed the INPULSIS® trials could receive nintedanib in an open-label extension trial (INPULSIS®-ON). Patients with FVC 50 % predicted at the start of INPULSIS®-ON, the absolute mean change in FVC from baseline to week 48 of INPULSIS®-ON was −62.3 and −87.9 mL, respectively (n = 24 and n = 558, r...
76 CitationsSource
#1Osamu Nishiyama (Kindai University)H-Index: 25
#2Ryo Yamazaki (Kindai University)H-Index: 4
Last. Yuji Tohda (Kindai University)H-Index: 22
view all 9 authors...
Emphysema on high-resolution computed tomography of the chest is the recent focus in the general practice in idiopathic pulmonary fibrosis (IPF). However, adequate attention has not been paid to obstructive disorder. Therefore, we retrospectively evaluated the association between the degree of airway obstruction and longevity in IPF subjects, with a hypothesis that lower forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) has an impact on prognosis. One hundred and fourteen c...
4 CitationsSource
Background: This document updates the American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association guideline on idiopathic pulmonary fibrosis treatment.Methods: Systematic reviews and, when appropriate, meta-analyses were performed to summarize all available evidence pertinent to our questions. The evidence was assessed using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach and then discussed by a m...
962 CitationsSource
#1Sakae Homma (Toho University)H-Index: 31
#2Keishi Sugino (Toho University)H-Index: 15
Last. Susumu Sakamoto (Toho University)H-Index: 19
view all 3 authors...
Abstract Since 1991, the severity of idiopathic pulmonary fibrosis (IPF) has been classified into 4 stages—stage I (characterized by a resting PaO 2 ≥80Torr), stage II (70–79Torr), stage III (60–69Torr), or stage IV ( 2 ) is 2 on exertion of 2 ≥70Torr (which includes most patients with stage III disease) at baseline would benefit from pirfenidone treatment. Recent post-marketing surveillance of 1370 patients—67.3% of whom had stage III/IV IPF—showed that pirfenidone was well-tolerated among thos...
37 CitationsSource
Cited By2
#1Shu Hisata (Jichi Medical University)H-Index: 10
#2Masashi Bando (Jichi Medical University)H-Index: 22
Last. Naohiko Inase (Tokyo Medical and Dental University)H-Index: 27
view all 19 authors...
Abstract Background Phase IV clinical trials in Western countries have reported that combined therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis (IPF) has a manageable safety profile. However, data on the long-term safety and tolerability of this combination treatment in the real-world setting in Japan are limited. Methods The retrospective data of 46 patients with IPF who received combination therapy with pirfenidone and nintedanib were obtained from 16 institutes in Japa...
Fibroblast growth factor receptor (FGFR) includes four highly conserved transmembrane receptor tyrosine kinases (FGFR1-4). FGF and FGFR regulate many biological processes, such as angiogenesis, wound healing and tissue regeneration. The abnormal expression of FGFR is related to the tumorigenesis, tumor progression and drug resistance of anti-tumor treatments in many types of tumors. Nowadays there are many anti-cancer drugs targeting FGFR. However, traditional single-target anti-tumor drugs are ...
1 CitationsSource